NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt

Core Viewpoint - NRx Pharmaceuticals has entered into a binding agreement for a registered direct offering of common stock and senior secured convertible promissory notes, aiming to raise a total of $8.9 million to support its drug development and operational funding [1][7]. Financing Details - The registered direct offering is expected to generate gross proceeds of$3.5 million, with approximately 1.2 million shares being issued at $2.88 per share [1][3]. - The company plans to issue senior secured convertible promissory notes with expected gross proceeds of$5.4 million, which will have an original discount of 8% and an interest rate of 6% per annum [1][4]. Use of Proceeds - The net proceeds from the financing will be utilized for filing New Drug Applications for NRX-100 and NRX-101, launching HOPE Therapeutics, and potentially acquiring new products for the pipeline [1][2][7]. - The funding is anticipated to support operations into 2026, alongside projected product sales and potential non-dilutive funding [1][7]. Product Development - NRx Pharmaceuticals is developing NRX-100 (IV ketamine) and NRX-101, both aimed at treating suicidal depression and PTSD, with plans to file for FDA approval [9][10]. - NRX-101 has been designated as an investigational Breakthrough Therapy by the FDA for treatment-resistant bipolar depression and chronic pain [9]. Strategic Partnerships - The company has received support from Anson Funds, which has expressed confidence in NRx's mission and its potential to transform the lives of patients with suicidal depression [2].